Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,012 total articles
MoonLake Immunotherapeutics has materially de‑risked its lead program after FDA confirmations and positive Week 40 Phase 3 data. With cash runway into late 2027 and an upcoming BLA submission in H2 2026, the stock looks positioned for a re-rating if 52‑week data and regulatory engagement continue to favor approval. We outline a long trade with entr…
Novo Nordisk ($NVO) has been hammered to the mid-$40s after a year of pricing and competitive concerns. The selloff has pushed the stock to a single-digit P/E near 10x and a market cap of about $204 billion. Management is buying shares back and core obesity/diabetes demand remains sizable. This trade idea proposes a buy at $46.50, with a $42.00 sto…
Whitbread will likely unlock material cash by selectively disposing of parts of its estate. If management executes disciplined estate recycling, proceeds can fund buybacks, debt paydown and reinvestment, supporting a mid-single-digit multiple re-rate. We initiate a tactical long aiming for ~15% annualized return, with defined entry, stop and target…
Micron enters earnings riding an AI-driven demand wave and fresh Anthropic ties. Fundamentals are strong - $1.37T market cap, $10.3B free cash flow, and ROE north of 33% - yet the stock sits near its 52-week high with stretched momentum. This trade idea sells into the next 10 trading days anticipating a post-earnings pullback even if results top ex…
Ondas agreed to acquire Cyberhawk for about $125 million, bringing $45M+ of expected revenue (95% recurring) and a $95M backlog. The market barely moved. Fundamentals and cash per share cushion the risk; valuation is rich but a deal-driven re-rating plus defense tailwinds create a defined risk-reward swing trade.
Moderna is staging a comeback after a strong run this year. With an FDA decision on its mRNA influenza candidate due 08/05/2026, solid clinical progress across multiple programs, $7.5B in cash and improving technicals, the stock looks set for another leg higher. This trade idea lays out an actionable swing entry, stop and target with rationale and …
Cadence Design Systems is trading at premium multiples - P/E ~90, P/FCF ~75 - but the company generates strong free cash flow, has a healthy balance sheet and sits at the center of AI-driven semiconductor design workflows. This trade idea takes a constructive, risk-managed long view: enter on modest weakness, stop below structural support, target r…
Micron's core memory business sits squarely in the bottleneck layer of the AI infrastructure buildout. With a $1.36T market cap, double-digit ROE, and a multi-year supply agreement with Anthropic, the stock can re-rate to $1,600 after a strong report on 06/24/2026. This trade plan gives a concrete entry, stop and target, with clear horizon and risk…
Meren Energy (MREN) is trading at deeply depressed levels after a year of sector-wide weakness. The company appears to offer an asymmetric risk-reward: a defined entry at $3.50, a protective stop at $2.80 and a first target at $6.00 as near-term catalysts and structural operational gains drive re-rating over the next 45 trading days.
Meta is turning generative and recommendation AI into measurable ad revenue gains faster than the market expects. With Q1-style ad growth already reported (33% ad growth cited), strong free cash flow ($48.25B), modest leverage (debt/equity ~0.24) and a sub-$1.5T market cap, Meta looks attractive at current levels. This is a tactical long with a cle…
Applied Materials (AMAT) sits at the intersection of accelerating chip complexity and nascent AR/AI wearables optics. The stock is trading near its 52-week high, but fundamentals - including $5.34B in free cash flow, 35.6% ROE and a market cap of roughly $508B - support a patient long trade. We lay out an actionable plan with entry at $640.00, stop…
Micron sits at the center of the AI memory cycle. Strong fundamentals, cash generation, strategic partnerships and constrained supply make MU my biggest position today. This note lays out why I’m not selling, the valuation framing, catalysts to watch, and a concrete trade plan with entry, stop and target alongside explicit risks.
Achieve Life Sciences (ACHV) faces regulatory cadence around its cytisinicline NDA, but a recent financing, positive program readouts and a modest enterprise value leave upside if the company can fix any FDA deficiencies. This trade idea lays out an entry at $5.10, a $9.00 target and a $3.50 stop, with a long-term horizon tied to regulatory resolut…
Western Digital (WDC) is trading well below an investment-case ceiling that assumes sustained AI-driven storage demand. Fundamentals show accelerating revenue and margin improvement, healthy free cash flow, and light leverage; technical momentum is strong but overbought. This trade is a long-term position (180 trading days) that aims to capture fur…
Arxis (ARXS) is a newly public aerospace components maker that looks like a classic high-quality compounder: diversified electronic and mechanical product lines, scale in defense and space supply chains, and momentum in both price and volume. The stock trades at a premium valuation, but fundamentals and tight short interest create a favorable asymm…
Advanced Micro Devices is trading near $552 after a blistering run. The company’s product mix - CPUs, GPUs, accelerators and adaptive SoCs - plus a clean balance sheet and accelerating AI deployments make a case for further share gains in AI infrastructure. Valuation is steep, so this is a conviction long with disciplined risk controls: entry $551.…
NetEase is trading at a reasonable valuation today (PE 16.3, market cap ~$78.4B) while accelerating international initiatives and selective investments in AI and IP partnerships. We see scope for a re-rating to a mid-teens-higher PE as overseas revenue scales and recurring streams (subscriptions, Yanxuan, Cloud Music) deepen. Trade idea: buy NTES a…
MakeMyTrip (MMYT) has faced heavy selling after a short-seller report and travel softness, but the core business - India’s leading online travel agency - still generates strong unit economics, holds a manageable balance sheet, and benefits from structural travel growth. The risk-reward at the current $46 area favors a measured long trade. Trade pla…
Hess Midstream (HESM) trades like a beaten-up midstream name but still generates strong free cash flow, pays a juicy distribution (~8-9% yield) and shows valuation metrics that justify a long trade on pullbacks. The business is regionally concentrated in the Bakken and levered to crude and produced-water services, but the balance sheet and cash gen…
InfuSystem (INFU) looks constructive after a period of consolidation. Fundamentals show positive free cash flow, improving returns and a reasonable EV/EBITDA multiple for a small-cap healthcare services name. Technicals and subdued short interest set up a likely mid-term breakout if volume picks up. This is a risk-managed swing trade for traders wi…
Intel is in a painful, capital-intensive transition that leaves the market split. Bulls assume a near-term land-grab from foundry and AI; bears assume the structural decline of Intel's CPU franchise and permanent margin erosion. Both views get three things wrong. This trade idea buys a defined-risk position that leans long while acknowledging execu…
Alibaba's push from cloud and models into a physical robotics stack - anchored by Qwen-Robot - creates a durable new revenue vector and margin lever. The shares trade at $105.10 with a market cap of $251.7B and a trailing P/E of 16.7, pricing in weaker growth. We see an asymmetric risk/reward if Qwen-Robot achieves scale in logistics, grocery, and …
Deutsche Telekom's ADR (DTEGY) has pulled back to $29.80 after a run from February highs. Fundamentals - a large market cap ($144.7B), low-teens P/E (14.7), and a 3.7% yield - plus structural catalysts around 5G network efficiency warrant a rating upgrade to attractive. This is a mid-term swing trade with a clear entry at $29.80, stop at $28.00 and…
Chord Energy combines a low leverage profile, meaningful free cash flow and a 4%+ dividend yield with operational upside from new recovery tech deployments. The stock trades below recent moving averages and offers a clear asymmetric risk-reward for a long-term (180 trading days) position.
Nano Labs (NA) is trading like a beaten semiconductor microcap while quietly shipping AI hardware, signing strategic MOUs for North America infrastructure, and showing insider conviction. The stock is cheap on a market-cap basis ($40.7M) with a P/E of ~2.1 and PB under 0.5. For risk-tolerant traders, a measured long with tight sizing can capture a …
